Pāriet uz galveno navigāciju Pāriet uz meklēšanu Pāriet uz galveno saturu

Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: A meta-analysis

  • Marco Castellana
  • , Giorgio Grani
  • , Maija Radziņa
  • , Vito Guerra
  • , Luca Giovanella
  • , Maurilio Deandrea
  • , Rose Ngu
  • , Cosimo Durante
  • , Pierpaolo Trimboli*
  • *Šī darba korespondējošais autors
    • Research Hospital
    • University of Rome La Sapienza
    • Paula Stradina Clinical University Hospital
    • Ente Ospedaliero Cantonale
    • University of Zurich
    • Ospedale Mauriziano Umberto I
    • Guy's and St Thomas' NHS Foundation Trust
    • Università della Svizzera italiana

    Zinātniskās darbības rezultāts: Devums žurnālam › Zinātniskais raksts (žurnālā) › koleģiāli recenzēts

    41 Atsauces (Scopus)

    Kopsavilkums

    Objective: Several thyroid imaging reporting and data systems (TIRADS) ha ve been proposed to stratify the malignancy risk of thyroid nodule by ultrasound. The TIRADS by the Europea n Thyroid Association, namely EU-TIRADS, was the last one to be published. Design: We conducted a meta-analysis to assess the prevalence of malig nancy in each EU-TIRADS class and the performance of EU-TIRADS class 5 vs 2, 3 and 4 in detecting mal ignant lesions. Methods: Four databases were searched until December 2019. Original art icles reporting the performance of EU-TIRADS and adopting histology as reference standard were inc luded. The number of malignant nodules in each class and the number of nodules classified as true/false positiv e/negative were extracted. A random-effects model was used for pooling data. Results: Seven studies were included, evaluating 5672 thyroid nodules. The prevalence of malignancy in each EU-TIRADS class was 0.5% (95% CI: 0.0-1.3), 5.9% (95% CI: 2.6-9 .2), 21.4% (95% CI: 11.1-31.7), and 76.1% (95% CI: 63.7-88.5). Sensitivity, specificity, PPV, NPV, LR+, LR- A nd DOR of EU-TIRADS class 5 were 83.5% (95% CI: 74.5-89.8), 84.3% (95% CI: 66.2-93.7), 76.1% (95% CI: 63.7-88.5), 85.4% (95 % CI: 79.1-91.8), 4.9 (95% CI: 2.9-8.2), 0.2 (95% CI: 0.1-0.3), and 24.5 (95% CI: 11.7-51.0), respectively. A further improved performance was found after excluding two studies because of limited sample size and low prevalence of ma lignancy in class 5. Conclusions: A limited number of studies generally conducted using a retros pective design was found. Acknowledging this limitation, the performance of EU-TIRADS in stratifying th e risk of thyroid nodules was high. Also, EU-TIRADS class 5 showed moderate evidence of detecting malignant lesions.

    OriģinālvalodaAngļu
    Lapas (no-līdz)255-264
    Lapu skaits10
    ŽurnālsEuropean Journal of Endocrinology
    Sējums183
    Izdevuma numurs3
    DOIs
    Publikācijas statussPublicēts - sept. 2020

    OECD Zinātnes nozare

    • 3. Medicīnas un veselības zinātnes

    Nospiedums

    Uzziniet vairāk par pētniecības tēmām “Performance of EU-TIRADS in malignancy risk stratification of thyroid nodules: A meta-analysis”. Kopā tie veido unikālu nospiedumu.

    Citēt šo